Vicriviroc/MK 2048

Drug Profile

Vicriviroc/MK 2048

Alternative Names: MK 2048/MK 4176; MK 2048/vicriviroc; MK 2048A IVR; MK 4176/MK 2048; VCV/MK 2048

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Naphthyridines; Piperazines; Pyrimidines; Pyrimidinones
  • Mechanism of Action CCR5 receptor antagonists; HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (Vaginal, Ring)
  • 17 Jul 2015 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for HIV infections (Prevention, In volunteers) in USA (NCT02419456)
  • 18 Jun 2015 Phase-I clinical trials in HIV infections (Prevention, In volunteers) in USA (Vaginal) (NCT02356302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top